J B Marriott

1.6k total citations
26 papers, 1.3k citations indexed

About

J B Marriott is a scholar working on Hematology, Immunology and Molecular Biology. According to data from OpenAlex, J B Marriott has authored 26 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Hematology, 11 papers in Immunology and 10 papers in Molecular Biology. Recurrent topics in J B Marriott's work include Multiple Myeloma Research and Treatments (11 papers), HIV Research and Treatment (5 papers) and Immune Cell Function and Interaction (4 papers). J B Marriott is often cited by papers focused on Multiple Myeloma Research and Treatments (11 papers), HIV Research and Treatment (5 papers) and Immune Cell Function and Interaction (4 papers). J B Marriott collaborates with scholars based in United Kingdom, Switzerland and Italy. J B Marriott's co-authors include Angus Dalgleish, George W. Muller, Keith Dredge, David Stirling, Sharon Cookson, Michael Westby, Ian Clarke, Mary Guckian, Roger Chen and Stephen Todryk and has published in prestigious journals such as The Journal of Immunology, British Journal of Cancer and AIDS.

In The Last Decade

J B Marriott

26 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J B Marriott United Kingdom 18 641 610 348 346 137 26 1.3k
James D. Levine United States 15 572 0.9× 818 1.3× 688 2.0× 629 1.8× 184 1.3× 38 1.9k
Roger Strair United States 21 783 1.2× 257 0.4× 203 0.6× 422 1.2× 180 1.3× 68 1.6k
Marie‐Françoise Bourgeade France 23 722 1.1× 231 0.4× 474 1.4× 379 1.1× 116 0.8× 46 1.5k
F Gavosto Italy 24 402 0.6× 829 1.4× 339 1.0× 401 1.2× 365 2.7× 112 1.6k
Ikuya Sakai Japan 17 419 0.7× 151 0.2× 299 0.9× 453 1.3× 101 0.7× 50 1.0k
Juraj Bodo United States 17 665 1.0× 252 0.4× 240 0.7× 354 1.0× 429 3.1× 48 1.3k
Yasuhiro Horii Japan 8 558 0.9× 591 1.0× 560 1.6× 700 2.0× 136 1.0× 14 1.6k
Nandini Kishore United States 15 451 0.7× 258 0.4× 690 2.0× 601 1.7× 203 1.5× 20 1.9k
Jake Shortt Australia 25 1.3k 2.1× 665 1.1× 493 1.4× 756 2.2× 270 2.0× 119 2.3k
Aristeidis Chaidos United Kingdom 20 578 0.9× 620 1.0× 309 0.9× 363 1.0× 317 2.3× 70 1.4k

Countries citing papers authored by J B Marriott

Since Specialization
Citations

This map shows the geographic impact of J B Marriott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J B Marriott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J B Marriott more than expected).

Fields of papers citing papers by J B Marriott

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J B Marriott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J B Marriott. The network helps show where J B Marriott may publish in the future.

Co-authorship network of co-authors of J B Marriott

This figure shows the co-authorship network connecting the top 25 collaborators of J B Marriott. A scholar is included among the top collaborators of J B Marriott based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J B Marriott. J B Marriott is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Marriott, J B, Ian Clarke, Anna Czajka, et al.. (2003). A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins.. PubMed. 63(3). 593–9. 45 indexed citations
2.
Dredge, Keith, Angus Dalgleish, & J B Marriott. (2003). Thalidomide analogs as emerging anti-cancer drugs. Anti-Cancer Drugs. 14(5). 331–335. 34 indexed citations
3.
Dredge, Keith, J B Marriott, Stephen Todryk, et al.. (2002). Protective Antitumor Immunity Induced by a Costimulatory Thalidomide Analog in Conjunction with Whole Tumor Cell Vaccination Is Mediated by Increased Th1-Type Immunity. The Journal of Immunology. 168(10). 4914–4919. 143 indexed citations
4.
Dredge, Keith, Angus Dalgleish, & J B Marriott. (2002). Recent developments in antiangiogenic therapy. Expert Opinion on Biological Therapy. 2(8). 953–966. 15 indexed citations
5.
Dredge, Keith, et al.. (2002). Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. British Journal of Cancer. 87(10). 1166–1172. 255 indexed citations
6.
Marriott, J B, George W. Muller, David Stirling, & Angus Dalgleish. (2001). Immunotherapeutic and antitumour potential of thalidomide analogues. Expert Opinion on Biological Therapy. 1(4). 675–682. 45 indexed citations
7.
Marriott, J B, et al.. (2000). Reduction in cytokine production in colorectal cancer patients: association with stage and reversal by resection. British Journal of Cancer. 82(5). 1009–1012. 82 indexed citations
8.
Zaninoni, Anna, et al.. (2000). The thalidomide analogue CC-3052 inhibits HIV-1 and tumour necrosis factor-alpha (TNF-α) expression in acutely and chronically infected cellsin vitro. Clinical & Experimental Immunology. 119(1). 123–129. 21 indexed citations
9.
Marriott, J B, George W. Muller, & Angus Dalgleish. (1999). Thalidomide as an emerging immunotherapeutic agent. Immunology Today. 20(12). 538–540. 103 indexed citations
10.
Souberbielle, Bernard, J B Marriott, Mike Westby, et al.. (1999). The conserved carboxy terminal region of HIV-1 gp120 is recognized by seronegative HIV-exposed people. AIDS. 13(18). 2515–2521. 15 indexed citations
11.
Marriott, J B, Michael Westby, Sharon Cookson, et al.. (1998). CC-3052: A Water-Soluble Analog of Thalidomide and Potent Inhibitor of Activation-Induced TNF-α Production. The Journal of Immunology. 161(8). 4236–4243. 72 indexed citations
12.
Rizzardi, Gian Paolo, J B Marriott, Sharon Cookson, et al.. (1998). Tumour necrosis factor (TNF) and TNF-related molecules in HIV-1+ individuals: relationship within vitroThl/Th2-type response. Clinical & Experimental Immunology. 114(1). 61–65. 20 indexed citations
13.
Marriott, J B. (1997). TNF-α antagonists: monoclonal antibodies, soluble receptors, thalidomide and other novel approaches. Expert Opinion on Investigational Drugs. 6(8). 1105–1108. 5 indexed citations
14.
Marriott, J B, Michael Westby, & Angus Dalgleish. (1997). Therapeutic potential of TNF-α inhibitors old and new. Drug Discovery Today. 2(7). 273–282. 42 indexed citations
15.
Barcellini, Wilma, Gian Paolo Rizzardi, J B Marriott, et al.. (1996). Interleukin-10-induced HIV-1 expression is mediated by induction of both membrane-bound tumour necrosis factor (TNF)-α receptor type 1 in a promonocytic cell line. AIDS. 10(8). 835–842. 20 indexed citations
16.
Marriott, J B, J. H. Goldman, Patrick J. Keeling, et al.. (1996). Abnormal cytokine profiles in patients with idiopathic dilated cardiomyopathy and their asymptomatic relatives.. Heart. 75(3). 287–290. 70 indexed citations
17.
Marriott, J B, Faieza Qasim, & David Oliveira. (1994). Anti-phospholipid Antibodies in the Mercuric Chloride Treated Brown Norway Rat. Journal of Autoimmunity. 7(4). 457–467. 7 indexed citations
18.
Marriott, J B & David Oliveira. (1994). Serial functional affinity of autoantibodies in anti-glomerular basement membrane disease. Clinical & Experimental Immunology. 95(3). 498–501. 3 indexed citations
19.
Marriott, J B, et al.. (1993). The use of proprietary medicines by patients presenting with peptic ulcer haemorrhage.. British Journal of Clinical Pharmacology. 35(5). 451–454. 3 indexed citations
20.
Marriott, J B & David Oliveira. (1993). Antimitochondrial autoantibodies in anti-glomerular basement membrane disease. Clinical & Experimental Immunology. 93(2). 259–264. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by James D. Levine Breakdown of academic impact, for papers by Roger Strair Breakdown of academic impact, for papers by Marie‐Françoise Bourgeade Breakdown of academic impact, for papers by F Gavosto Breakdown of academic impact, for papers by Ikuya Sakai Breakdown of academic impact, for papers by Juraj Bodo Breakdown of academic impact, for papers by Yasuhiro Horii Breakdown of academic impact, for papers by Nandini Kishore Breakdown of academic impact, for papers by Jake Shortt Breakdown of academic impact, for papers by Aristeidis Chaidos
Rankless by CCL
2026